Compare Stocks: ACXP, TAOX, AYTU, and ABVC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.90 -6.2%	$1.30	$0.86 ▼ $3.40	$23.90M	0.57	96,654 shs	116,752 shs
ACXP Acurx Pharmaceuticals	$1.40 -5.7%	$1.52	$1.31 ▼ $8.34	$6M	-2.03	95,992 shs	607,919 shs
AYTU Aytu BioPharma	$2.38 +3.5%	$2.21	$1.65 ▼ $3.07	$25.54M	0.25	27,729 shs	55,617 shs
TAOX Synaptogenix	$3.44 -1.1%	$3.61	$3.18 ▼ $10.00	$25.70M	1.45	91,081 shs	57,160 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-11.77%	-25.63%	-17.44%	-69.70%
ACXP Acurx Pharmaceuticals	0.00%	-9.42%	-12.26%	-27.34%	-70.44%
AYTU Aytu BioPharma	0.00%	+0.85%	+10.19%	+8.68%	+3.93%
TAOX Synaptogenix	0.00%	+2.08%	-2.82%	-34.10%	-64.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.90 -6.2%	$1.30	$0.86 ▼ $3.40	$23.90M	0.57	96,654 shs	116,752 shs
ACXP Acurx Pharmaceuticals	$1.40 -5.7%	$1.52	$1.31 ▼ $8.34	$6M	-2.03	95,992 shs	607,919 shs
AYTU Aytu BioPharma	$2.38 +3.5%	$2.21	$1.65 ▼ $3.07	$25.54M	0.25	27,729 shs	55,617 shs
TAOX Synaptogenix	$3.44 -1.1%	$3.61	$3.18 ▼ $10.00	$25.70M	1.45	91,081 shs	57,160 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-11.77%	-25.63%	-17.44%	-69.70%
ACXP Acurx Pharmaceuticals	0.00%	-9.42%	-12.26%	-27.34%	-70.44%
AYTU Aytu BioPharma	0.00%	+0.85%	+10.19%	+8.68%	+3.93%
TAOX Synaptogenix	0.00%	+2.08%	-2.82%	-34.10%	-64.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ACXP Acurx Pharmaceuticals	2.00	Hold	$31.00	2,122.22% Upside
AYTU Aytu BioPharma	2.25	Hold	$10.75	351.68% Upside
TAOX Synaptogenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACXP, TAOX, AYTU, and ABVC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	ACXP Acurx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TAOX Synaptogenix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $14.50
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	46.85	N/A	N/A	$0.46 per share	1.96
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.07 per share	N/A
AYTU Aytu BioPharma	$66.38M	0.38	$0.38 per share	6.34	$2.11 per share	1.13
TAOX Synaptogenix	$687.84K	37.37	N/A	N/A	$2.83 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	8/18/2026 (Estimated)
ACXP Acurx Pharmaceuticals	-$7.97M	-$2.69	N/A	N/A	N/A	N/A	-141.45%	-96.50%	N/A
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	9.52	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
TAOX Synaptogenix	-$28.74M	-$13.28	N/A	N/A	N/A	-2,153.97%	-116.74%	-93.67%	N/A

Latest ACXP, TAOX, AYTU, and ABVC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ACXP Acurx Pharmaceuticals	-$0.3767	-$0.53	-$0.1533	-$0.53	N/A	N/A
8/13/2026	Q2 2026	TAOX Synaptogenix	N/A	-$1.83	N/A	-$1.83	N/A	$0.09 million
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
5/18/2026	Q1 2026	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.12
ACXP Acurx Pharmaceuticals	N/A	3.78	3.78
AYTU Aytu BioPharma	0.27	1.12	1.00
TAOX Synaptogenix	N/A	27.39	27.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ACXP Acurx Pharmaceuticals	11.53%
AYTU Aytu BioPharma	33.49%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ACXP Acurx Pharmaceuticals	20.30%
AYTU Aytu BioPharma	4.90%
TAOX Synaptogenix	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.55 million	21.51 million	Not Optionable
ACXP Acurx Pharmaceuticals	3	4.30 million	3.43 million	No Data
AYTU Aytu BioPharma	160	10.73 million	10.21 million	Not Optionable
TAOX Synaptogenix	4	7.47 million	7.27 million	N/A

ACXP, TAOX, AYTU, and ABVC Headlines

Recent News About These Companies

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

July 8, 2026 | prnewswire.com

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

June 16, 2026 | prnewswire.com

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

November 18, 2025 | prnewswire.com

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

November 11, 2025 | prnewswire.com

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

November 4, 2025 | prnewswire.com

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

October 20, 2025 | prnewswire.com

TAO Synergies Announces $11 Million Private Placement

October 13, 2025 | prnewswire.com

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

September 22, 2025 | prnewswire.com

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

September 8, 2025 | prnewswire.com

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

July 1, 2025 | prnewswire.com

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

June 26, 2025 | prnewswire.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin

June 26, 2025 | kxan.comK

Synaptogenix begins TAO acquisition as part of crypto treasury strategy

June 26, 2025 | uk.investing.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA

June 26, 2025 | ktla.comK

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

June 24, 2025 | prnewswire.com

Synaptogenix Unveils TAO-Focused Crypto Treasury Plan

June 10, 2025 | livebitcoinnews.comL

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

June 9, 2025 | prnewswire.com

Synaptogenix Inc Ordinary Shares

January 3, 2025 | morningstar.comM

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

December 20, 2024 | prnewswire.com

Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary

October 7, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, TAOX, AYTU, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$0.90 -0.06 (-6.20%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$0.94 +0.04 (+4.79%)

As of 08/14/2026 07:57 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Acurx Pharmaceuticals NASDAQ:ACXP

$1.40 -0.09 (-5.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.38 -0.02 (-1.29%)

As of 08/14/2026 07:55 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Aytu BioPharma NASDAQ:AYTU

$2.38 +0.08 (+3.48%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.38 +0.00 (+0.21%)

As of 08/14/2026 07:34 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Synaptogenix NASDAQ:TAOX

$3.44 -0.04 (-1.15%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.46 +0.02 (+0.58%)

As of 08/14/2026 07:34 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, TAOX, AYTU, and ABVC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, TAOX, AYTU, and ABVC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, TAOX, AYTU, and ABVC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, TAOX, AYTU, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Acurx Pharmaceuticals NASDAQ:ACXP

Aytu BioPharma NASDAQ:AYTU

Synaptogenix NASDAQ:TAOX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, TAOX, AYTU, and ABVC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, TAOX, AYTU, and ABVC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, TAOX, AYTU, and ABVC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, TAOX, AYTU, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Acurx Pharmaceuticals NASDAQ:ACXP

Aytu BioPharma NASDAQ:AYTU

Synaptogenix NASDAQ:TAOX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools